Genomes and Genes
Summary: Treatment of diseases with biological materials or biological response modifiers, such as the use of GENES; CELLS; TISSUES; organs; SERUM; VACCINES; and humoral agents.
Publications244 found, 100 shown here
- Biologic therapies in autoimmune diseasesHenry Penn
Department of Rheumatology, Royal Free Hospital, London
Clin Med 6:105-8. 2006..This review briefly summarises the established uses of biologic therapies in rheumatoid disease, and outlines other diseases in rheumatology and other fields where biologic agents are finding a role...
- Campylobacter bacteriophages and bacteriophage therapyP L Connerton
School of Biosciences, Division of Food Sciences, University of Nottingham, Loughborough Leics, UK
J Appl Microbiol 111:255-65. 2011..The evolutionary consequences of naturally occurring bacteriophage infection that have come to light through investigations of bacteriophages in the poultry ecosystem will also be discussed...
- High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteriaMatthew J Hamilton
Department of Soil, Water and Climate, BioTechnology Institute and Microbial and Plant Genomics Institute, University of Minnesota, St Paul, MN, USA
Gut Microbes 4:125-35. 2013..Our results demonstrate that frozen fecal microbiota from a healthy donor can be used to effectively treat recurrent CDI resulting in restoration of the structure of gut microbiota and clearing of Clostridum difficile...
- Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapyAnne Bruttin
Nestle Research Center, Nestec Ltd, Vers chez les Blanc, CH 1000 Lausanne 26, Switzerland
Antimicrob Agents Chemother 49:2874-8. 2005..This is, to our knowledge, the first safety test in the recent English literature which has measured the bioavailability of oral phage in humans and is thus a first step to the rational evaluation of phage therapy for diarrheal diseases...
- Characterization of JG024, a pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditionsJulia Garbe
Institute of Microbiology, Technische Universitat Braunschweig, Spielmannstr, 7, 38106 Braunschweig, Germany
BMC Microbiol 10:301. 2010..Phage therapy is an alternative to treat these chronic P. aeruginosa infections. However, little is known about the factors which influence phage infection of P. aeruginosa under infection conditions and suitable broad host range phages...
- Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patientsChristina Jorup-Rönström
Stockholm South General Hospital, Sjukhusbacken 10, Stockholm, Sweden
Scand J Gastroenterol 47:548-52. 2012..To the best of our knowledge, this is the first time a fecal culture of microbes has retained the possibility for years to cure a substantial number of patients with CDAD...
- Genome dynamics of Campylobacter jejuni in response to bacteriophage predationAndrew E Scott
Division of Food Sciences, University of Nottingham, Loughborough, United Kingdom
PLoS Pathog 3:e119. 2007..jejuni exists in vivo as families of related meta-genomes generated to survive local environmental pressures...
- Biological therapies for inflammatory bowel diseasesPaul Rutgeerts
Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
Gastroenterology 136:1182-97. 2009..The efficacy of each therapy must be shown in carefully designed clinical programs. Biological therapies carry a definite safety risk, so their place in treatment algorithms must be defined carefully...
- Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case seriesTimothy A Rubin
Essentia Health Duluth Clinic Digestive Health Center, Duluth, MN, USA
Anaerobe 19:22-6. 2013..difficile infection (RCDI) has become increasingly frequent, and alternative treatments are needed. We examined the efficacy of fecal microbiota transplantation (FMT) instilled into the upper gastrointestinal tract for RCDI...
- The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 programJames M Balwit
Society for Immunotherapy of Cancer, Milwaukee, WI, USA
J Transl Med 9:18. 2011The Society for Immunotherapy of Cancer, SITC (formerly the International Society for Biological Therapy of Cancer, iSBTc), aims to improve cancer patient outcomes by advancing the science, development and application of biological ..
- Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy)M Sánchez-Regaña
Department of Dermatology, Psoriasis and Phototherapy Center, Hospital Universitari Sagrat Cor, Barcelona, Spain
J Eur Acad Dermatol Venereol 25:579-86. 2011..Nail psoriasis represents a challenge for specialists. There is no comparative study of systemic treatment's effectiveness at this site...
- Growth factor receptor expression and remodeling of saccular cerebral artery aneurysm walls: implications for biological therapy preventing ruptureJuhana Frösen
Neurosurgery Research Group, Biomedicum Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Neurosurgery 58:534-41; discussion 534-41. 2006..The receptors regulating SCAA wall remodeling are, however, unknown...
- Biological therapy of inflammatory bowel diseaseDanuta Owczarek
Department of Gastroenterology and Hepatology, Jagiellonian University, Medical College, Krakow, Poland
Pol Arch Med Wewn 119:84-8. 2009..commonly fails to bring satisfactory results, therefore an interest in new therapeutic options, that is, biological therapy, gene therapy, hematopoietic stem cell transplantation, and leucapheresis, has aroused recently...
- The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapyRoy S Herbst
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 95:340-53. 2002..The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC...
- Fecal microbiota transplantation: techniques, applications, and issuesThomas Julius Borody
Centre for Digestive Diseases, Level 1, 229 Great North Road, Five Dock, New South Wales 2046, Australia
Gastroenterol Clin North Am 41:781-803. 2012....
- Role of biological therapy for inflammatory bowel disease in developing countriesGerhard Rogler
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
Gut 61:706-12. 2012..If IBD emerges to the same extent in those countries as it has in the West, the need for biological therapy will increase dramatically, and the pharmaceutical industry, healthcare providers, patient advocate groups, ..
- Economical aspect of biological therapy in inflammatory conditions in HungaryJudit Laki
Department of Medical Expertise, Clinical Auditing and Analysis, National Health Insurance Fund Administration, Váci út 73 A, 1139 Budapest, Hungary
Expert Opin Biol Ther 13:327-37. 2013..All biological agents except rituximab were first line therapies; rituximab was a second line option in rheumatoid arthritis...
- Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosisMilan Buc
Department of Immunology, Comenius University School of Medicine, 813 72 Bratislava, Slovakia
Mediators Inflamm 2013:963748. 2013..Furthermore, we discuss how laboratory immunology can offer physicians its help in the diagnosis process and decisions what kind of biological therapy should be used.
- Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapyR Duarte
Centro de Referência de Tuberculose Multi resistente da Região Norte
Acta Reumatol Port 37:253-9. 2012..Chronic immunosuppression is a known risk factor for tuberculosis. Our aim was to reach a consensus on screening and prevention of tuberculosis in patients with immune mediated inflammatory diseases candidates to biologic therapy...
- Safety of biologic therapy in rheumatoid arthritisRobert S Woodrick
Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, 240 East Huron Street, McGaw M300, Chicago, IL 60611, USA
Nat Rev Rheumatol 7:639-52. 2011..With careful patient selection and appropriate vigilance on the part of treating physicians and other care providers, these compounds can be safely integrated into the therapeutic plan...
- Bacteriophage biocontrol in animals and meat productsR J Atterbury
School of Clinical Veterinary Science, University of Bristol, Langford, Bristol BS40 5DU, UK
Microb Biotechnol 2:601-12. 2009..This review will provide a brief overview of the history of PT in the West and will summarize some of the key findings of phage biocontrol studies in animals and meat products...
- Biological therapies of autoimmune diseasesIrene S Kourbeti
Internal Medicine, University Hospital, Medical School, University of Crete, Heraklion, Greece
Curr Drug Targets Inflamm Allergy 4:41-6. 2005..Susceptibility to infections has always been a major concern; a high level of suspicion is necessary and strategies should be implemented for the prevention, the rapid identification and pre-emptive therapy of such infections...
- Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanerceptJerry Bagel
Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey 08520, USA
J Am Acad Dermatol 67:86-92. 2012..Biologic therapies are used to treat moderate to severe psoriasis, but evidence from randomized, controlled studies is lacking regarding scalp-related effectiveness...
- Complete objective response to biological therapy of plurifocal breast carcinomaGiuseppe Di Bella
Di Bella Foundation, Bologna, Italy
Neuro Endocrinol Lett 29:857-66. 2008In this case presentation, a woman with breast carcinoma who chose to try Prof. L. DiBella's biological therapy (MDB), was found, after seven months, to have a 50% reduction in objective measures of her carcinoma and was totally cured ..
- Pharmacokinetic principles of bacteriophage therapyRobert J H Payne
School of Biological Sciences, Royal Holloway, University of London, London, UK
Clin Pharmacokinet 42:315-25. 2003..Understanding such formulae is important for interpreting data and guiding experimental design. Tailoring pharmacokinetic models for specific systems needs to become standard practice in future studies...
- Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infectionLisa A Carmody
Department of Pediatrics and Communicable Disease, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
J Infect Dis 201:264-71. 2010..cenocepacia lung infection model. Systemic phage administration was more effective than inhalational administration, suggesting that circulating phages have better access to bacteria in lungs than do topical phages...
- Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections NetworkKevin L Winthrop
Oregon Health and Sciences University, Portland 97239, USA
Clin Infect Dis 46:1738-40. 2008..Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context...
- Bifidobacteria inhibit the inflammatory response induced by gliadins in intestinal epithelial cells via modifications of toxic peptide generation during digestionJ M Laparra
Instituto de Agroquimica y Tecnologia de Alimentos CSIC, Burjassot Valencia, Spain
J Cell Biochem 109:801-7. 2010..Therefore, bifidobacteria change the gliadin-derived peptide pattern and, thereby, attenuate their pro-inflammatory effects on Caco-2 cells...
- Bacteriophage for biocontrol of foodborne pathogens: calculations and considerationsSteven Hagens
EBI Food Safety, Nieuwe Kanaal 7P, 6709 PA Wageningen, The Netherlands
Curr Pharm Biotechnol 11:58-68. 2010..This review will discuss these issues on the basis of the available literature as well as providing an outlook on the potential of phages in future applications...
- European regulatory conundrum of phage therapyGilbert Verbeken
Hospital Center of the Base Queen Astrid, Laboratory for Molecular and Cellular Technology, Burn Unit, Bruynstraat 1, B 1120 Neder over Heembeek, Belgium
Future Microbiol 2:485-91. 2007..As a long-term solution, however, we suggest the creation of a specific section for phage therapy under the Advanced Therapy Medicinal Product Regulation...
- Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis modelTakeaki Matsuda
Department of Surgery, Weill Medical College of Cornell University, New York, USA
Surgery 137:639-46. 2005..This may minimize systemic cytokine responses and limit inflammation in bacterial sepsis. We determined the effects of t amber A3 T4 LyD and virulent wild-type (WT) phages on mouse bacterial peritonitis...
- Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis--case reportS Letkiewicz
Urological and Andrological Clinic UROGEN, 42 600, Tarnowskie Góry, Poland
Folia Microbiol (Praha) 54:457-61. 2009....
- Biological therapy update in colorectal cancerSteven M Sorscher
Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8056, St Louis, MO 63110, USA
Expert Opin Biol Ther 7:509-19. 2007....
- Infectious complications of biological therapyNigil Haroon
Toronto Western Research Institute, University of Toronto, Ontario, Canada
Curr Opin Rheumatol 21:397-403. 2009Although the remarkable efficacy of biological therapy has resulted in significant success in rheumatic disease management, susceptibility to infections remains a concern...
- The risk of infections with biologic therapies for rheumatoid arthritisDaniel E Furst
University of California Los Angeles, Los Angeles, CA 90095 1670, USA
Semin Arthritis Rheum 39:327-46. 2010..To assess the risk of serious and nonserious bacterial and viral infections associated with the use of biologic therapy (abatacept, adalimumab, anakinra, etanercept, infliximab, and rituximab) in patients with rheumatoid arthritis (RA)...
- Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trialD D Rhoads
Department of Psychiatry, University of Minnesota, Minneapolis, USA
J Wound Care 18:237-8, 240-3. 2009..This phase 1 trial set out to examine the safety of a bacteriophage-based preparation for difficult-to-treat wounds...
- Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapyRonan H Mullan
St Vincent s University Hospital, Dublin, Ireland
Arthritis Rheum 56:2919-28. 2007....
- Set a microbe to kill a microbe: drug resistance renews interest in phage therapyPaul D Thacker
JAMA 290:3183-5. 2003
- Replication-selective virotherapy for cancer: Biological principles, risk management and future directionsD Kirn
Viral and Genetic Therapy Programme, Imperial College School of Medicine and the Imperial Cancer Research Fund, Hammersmith Hospital, London, UK
Nat Med 7:781-7. 2001..This review describes the underlying biological principles and current status of the field, outlines approaches for improving clinical effectiveness and discusses the unique safety and regulatory issues surrounding viral therapies...
- Biological therapy and nail psoriasisMonica Lawry
Nail Disease Clinic, UC Davis, Department of Dermatology, Sacramento, California 95825, USA
Dermatol Ther 20:60-7. 2007..b>Biological therapy for psoriasis and psoriatic arthritis is now widely used, and early evidence indicates it may have ..
- Optimal bacteriophage mutation rates for phage therapyDavid T Kysela
Department of Ecology and Evolutionary Biology, Yale University, P O Box 208106, New Haven, CT 06520 8106, USA
J Theor Biol 249:411-21. 2007..01). Increases to the mutation rate beyond the optimal value at mutation-selection balance may therefore prove generally undesirable...
- Summary of the primer on tumor immunology and the biological therapy of cancerYufeng Li
Department of Melanoma Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston, TX, USA
J Transl Med 7:11. 2009The International Society for Biological Therapy of Cancer (iSBTc) is one of the "premier destinations for interaction and innovation in the cancer biologics community"...
- Hormone-biological therapy in breast cancer: preclinical evidences, clinical studies and future directionsGaia Schiavon
Department of Oncology, University Campus Bio Medico, Rome, Italy
Curr Cancer Drug Targets 10:3-18. 2010..The evidence of a cross-talk among signaling pathways and the recent advances in understanding biology of this neoplasm have led to the new concept of hormone-biological therapy.
- Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimuriumMing Zhao
AntiCancer, 7917 Ostrow Street, San Diego, CA 92111 3604, USA
Proc Natl Acad Sci U S A 102:755-60. 2005..This result is in marked contrast to bacteria previously tried for cancer therapy that were confined to necrotic areas of the tumor, which may account, in part, for the strain's unique antitumor efficacy...
- Treatment and management of psoriasis with nail involvement: a focus on biologic therapyRichard G Langley
Queen Elizabeth II Health Sciences Centre, Dalhousie University, 1278 University Avenue, Halifax, Nova Scotia, Canada
Dermatology 221:29-42. 2010..The extra disease burden that nail symptoms place on the patient can be considered indicative of a more severe form of the disease and should be taken into consideration when assessing treatment options...
- Soluble cytokine receptors in biological therapyRafael Fernandez-Botran
Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, KY 40292, USA
Expert Opin Biol Ther 2:585-605. 2002..Two current areas of research are the identification of their most promising applications and characterisation of their long-term effects...
- Effectiveness of a 'hunter' virus in controlling human immunodeficiency virus type 1 infectionGisela Garcia-Ramos
Department of Biology, University of Kentucky, Lexington, KY 40506, USA
J Gen Virol 91:2513-23. 2010..This study indicates that hunter viruses may halt the progression of the HIV infection by restoring and sustaining high CD4(+) T-cell levels...
- Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in miceRyohei Watanabe
Third Department of Surgery, Toho University School of Medicine, Tokyo, Japan
Antimicrob Agents Chemother 51:446-52. 2007..In conclusion, our findings suggest that oral administration of phage may be effective against gut-derived sepsis caused by P. aeruginosa...
- Polymeric human Fc-fusion proteins with modified effector functionsDavid N A Mekhaiel
Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
Sci Rep 1:124. 2011..Overall, these findings establish an effective IgG Fc-fusion based polymeric platform with which the therapeutic and vaccination applications of Fc-fusion immune-complexes can now be explored...
- Complications of biological therapy for inflammatory bowel diseasesWojciech Blonski
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Curr Opin Gastroenterol 22:30-43. 2006..The purpose of this review is to analyze the complications associated with treatment of inflammatory bowel disease with biologic agents...
- Biological therapy for ulcerative colitis: what is after anti-TNFGionata Fiorino
IBD Center, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy
Curr Drug Targets 12:1433-9. 2011..New therapeutic options, such as, biological therapy, gene therapy, hematopoietic stem cell transplantation, and leucoapheresis, have been investigated recently...
- Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virusSteve H Thorne
Bio X Program, Dept of Pediatrics, School of Medicine, Stanford University, CA, USA
Expert Opin Biol Ther 4:1307-21. 2004....
- Biological therapy for psoriasisSuzanne E Clements
The Dermatology Centre, The University of Manchester, Hope Hospital, Salford
Br J Hosp Med (Lond) 67:184-7. 2006
- Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO)M L Hetland
Department of Rheumatology, Copenhagen University Hospitals at Hvidovre, Denmark
Scand J Rheumatol 34:40-4. 2005..To present from the Danish Database for Biological Therapies in Rheumatology (DANBIO) the frequencies and types of adverse events as well as risk factors during treatment with biological agents in clinical practice...
- Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysisKristian Reich
Dermatologikum Hamburg, Hamburg, Germany
Curr Med Res Opin 24:1237-54. 2008..The comparative effects of biological response modifiers (BRMs) on the severity of psoriasis and its effects on health-related quality of life (HRQoL) have not been evaluated...
- Safety issues with biological therapies for inflammatory bowel diseaseGert Van Assche
Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
Curr Opin Gastroenterol 22:370-6. 2006The purpose of this review is to summarize recent evidence describing specific complications associated with the use of biological therapy derived from controlled trials and from post-marketing surveillance.
- Emerging biological therapies in systemic lupus erythematosusG R Mount
Division of Rheumatology, Department of Medicine, Uniformed Services University, Bethesda, Maryland, USA
Clin Pharmacol Ther 83:167-71. 2008..Effective treatment must be individualized and is often based on the specific manifestations that are seen in each patient. In a similar manner, prognosis is also dependent on the severity and the specific organ systems involved...
- Rheumatoid arthritis: new developments in biologic therapyAnnil Mahajan
Postgraduate Department of General Medicine, Government Medical College, Jammu 180016
J Indian Med Assoc 104:327-30. 2006..To date combination therapy of methotrexate plus a single biologic has been widely studied with synergistic effect. Etanercept and infliximab are two biologics available in India...
- Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancerDaniel Albo
Michael E DeBakey Department of Surgery, Baylor College of Medicine, Michael E DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, OCL 112A, Houston, TX 77030, USA
Surg Oncol Clin N Am 17:357-76, ix. 2008..Although a clear "magic bullet" has yet to emerge, this type of targeted approach offers hope in the management of this dreadful disease. This article offers an update on these promising diagnostic and treatment modalities...
- [Treatment of ANCA-associated vascularitides]Loic Guillevin
Service de Medecine Interne, Centre de référence national, Plan maladies rares, vascularites et sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris 5 Rene Descartes, Paris, France
Presse Med 36:922-7. 2007..These biologics must be prescribed extremely cautiously and only in trial settings, especially in view of the adverse effects, few but severe, recently been reported with them...
- Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatmentsP C M van de Kerkhof
Department of Dermatology, University Hospital Nijmegen, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
J Eur Acad Dermatol Venereol 20:639-50. 2006....
- The effect of weight on the efficacy of biologic therapy in patients with psoriasisLily Clark
Department of Dermatology at Columbia University, New York, New York, USA
J Am Acad Dermatol 58:443-6. 2008..Patients with psoriasis, in particular, tend to be above normal weight. Three of the 5 biologics used to treat psoriasis are fixed-dosed treatments: alefacept, etanercept, and adalimumab. Dosing regimens do not account for weight...
- Biologic therapy in psoriasisAlka Dogra
Department of Dermatology, Venereology and Leprology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
Indian J Dermatol Venereol Leprol 72:256-64; quiz 265. 2006
- Review article: biological drugs in Crohn's diseaseM A Kamm
St Mark s Hospital, Harrow, Middlesex, UK
Aliment Pharmacol Ther 24:80-9. 2006..Screening for tuberculosis (TB) diminishes the rate of TB activation. Biological drugs can offer great therapeutic benefit, but their use must be considered in context...
- Biologic response modifier therapy for psoriatic ocular inflammatory diseaseNancy Huynh
Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts 02142, USA
Ocul Immunol Inflamm 16:89-93. 2008..To evaluate the efficacy and safety of biologic response modifiers (BRMs) in the treatment of patients with psoriatic ocular inflammatory disease...
- [Biotherapies for the treatment of asthma: are they the treatment of the future?]A B Tonnel
Service de Pneumologie et Immunoallergologie, CHRU de Lille 59037 Lille Cedex
Rev Mal Respir 23:10S44-10S48. 2006
- Biologic therapies in juvenile idiopathic arthritis: why and for whom?L J McCann
Royal Liverpool NHS Trust, Alder Hey, Liverpool
Acta Reumatol Port 32:15-26. 2007..This article reviews the current biologic treatment options available for children with arthritis and the evidence base that supports their use...
- Biologic therapeutics in the treatment of psoriasis. Part 1: reviewRichard G Langley
Department of Medicine, Dalhousie University, Halifax, NS, Canada
J Cutan Med Surg 11:99-122. 2007....
- [Rheumatoid arthritis: current status of therapy]Dalila Mrabet El Bahri
Service de Rhumatologie, Hopital La Rabta, Tunis, Tunisie
Tunis Med 85:1-8. 2007..It is also essential to assure a strict follow-up in patients under biotherapy to detect adverse events that can be sometimes severe. Thus, the ratio benefit/risk must be evaluated before any biotherapy prescription...
- Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel diseaseArthur Barrie
Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
Inflamm Bowel Dis 13:1424-9. 2007..This article reviews the therapeutic experiences of the 2 most widely used anti-TNF neutralizing antibodies, infliximab and adalimumab, for immune-mediated EIM of IBD...
- The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasisR P Katugampola
Department of Dermatology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK
Br J Dermatol 156:945-50. 2007..However, these reports only give limited interpretation of the meaning of Dermatology Life Quality Index (DLQI) scores and provide limited comparison data...
- An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic optionsArgentina Leon
University of Miami, Miller School of Medicine, Miami, FL, USA
Expert Opin Pharmacother 8:617-32. 2007....
- Sequential therapies for Crohn's disease: optimizing conventional and biologic strategiesShani Desilva
Inflammatory Bowel Disease Clinic, Gastroenterology Training Program, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
Rev Gastroenterol Disord 8:109-16. 2008..Emerging data suggest that earlier use of biological therapy is associated with improved clinical outcomes and potential disease-modifying effects...
- Biologic therapies in psoriasis: a new therapeutic approachPaolo Gisondi
Section of Dermatology and Venereology, Department of Biomedical and Surgical Sciences, University of Verona, Piazzale A Stefani 1, 37126, Verona, Italy
Autoimmun Rev 6:515-9. 2007..Moreover, efficacy can reduce over time. Etanercept is moderately active but has a better safety profile, and can be discontinued and re-used without loss of efficacy. The long term safety of all these agents has not been established...
- International guidelines on access to biologic therapy: why the differences and which is best?Chris Deighton
Derbyshire Royal Infirmary, Department of Rheumatology, Derby, UK
Nat Clin Pract Rheumatol 4:520-1. 2008
- COMET's path, and the new biologicals in rheumatoid arthritisJoel M Kremer
Center for Rheumatology, Albany Medical College, Albany, NY 12206, USA
Lancet 372:347-8. 2008
- Safety of biologic therapyWojciech Blonski
Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland
Inflamm Bowel Dis 13:769-96. 2007..This is because it has been evaluated in many more trials than has any other biologic agent. In addition, postmarketing experience provides very valuable information about adverse events occurring during treatment with this agent...
- Treatment with biologic therapies and the risk of cancer in patients with IBDLivia Biancone
Università Tor Vergata of Rome, Italy
Nat Clin Pract Gastroenterol Hepatol 4:78-91. 2007..Multicenter, case-control studies in large populations, with a long-term follow-up are needed to define the outcome of patients with IBD treated with biologic therapies...
- The pitfalls in the development of biologic therapyRavinder N Maini
Nat Clin Pract Rheumatol 3:1. 2007
- Safety of infliximab and other biologic agents in the inflammatory bowel diseasesJagadeshwar G Reddy
General Internal Medicine, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
Gastroenterol Clin North Am 35:837-55. 2006..Proper selection of candidates for anti-TNF-alpha therapy is critical in maintaining a proper benefit-to-risk ratio...
- A review of biologic treatments for psoriasis with emphasis on infliximabS Pirzada
Dalhousie University, Halifax, Canada
Skin Therapy Lett 12:1-4. 2007..Real world experience with this class of drugs is expanding and more new biologics are becoming available...
- Understanding the new clinical landscape for psoriasis: a comparative review of biologicsDaniel N Sauder
Department of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 0900, USA
J Cutan Med Surg 8:205-12. 2004..Encouraging results from clinical trials suggest that biologic therapies are effective treatments for psoriasis...
- [Drug therapy and nutrition therapy of a young patient with Crohn disease]Matti Verkasalo
HUS n lasten ja nuorten sairaala, Lastenklinikka PL 281, 00029 HUS
Duodecim 119:617-24. 2003
- New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: a personal appraisal of their use in practiceJeffrey P Callen
Division of Dermatology, University of Loisville School of Medicine, Louisville, Kentucky 40202, USA
J Am Acad Dermatol 49:351-6. 2003
- Emerging biological therapies in rheumatoid arthritisXavier Mariette
Rheumatology Department, INSERM EMI 109, Bicêtre Teaching Hospital, Paris Sud University, Le Kremlin Bicetre, France
Joint Bone Spine 71:470-4. 2004..One of the challenges for the future is to identify ingenious combinations of biological therapies capable of improving the quality and duration of responses without exacerbating side effects...
- How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's diseaseWilliam J Sandborn
Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Rev Gastroenterol Disord 4:S25-33. 2004..Some, or all, of these therapies will likely represent important treatments for Crohn's disease in the future...
- Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studiesStephen B Hanauer
Section of Gastroenterology and Nutrition, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
Rev Gastroenterol Disord 4:S18-24. 2004..This review discusses the results of controlled clinical trials of anti-TNF agents for Crohn's disease...
- Why do anti-tumor necrosis factor antibodies work in Crohn's disease?Bruce E Sands
Gastrointestinal Unit and MGH Inflammatory Bowel Disease Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Rev Gastroenterol Disord 4:S10-7. 2004..Transmembrane binding of TNF effects apoptosis of T cells, thereby alleviating a fundamental defect in Crohn's disease in the regulation of T cell populations...
- Biological therapies in the spondyloarthritides--the current stateJ Braun
Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
Rheumatology (Oxford) 43:1072-84. 2004..Complicated infections including tuberculosis have been reported. These can largely be prevented by appropriate screening. As it stands now, the benefits of anti-TNF therapy in AS seem to outweigh these shortcomings...
- Novel biologic therapies for psoriasisJane Barry
Adelaide and Meath Hospital Dublin, Incorporating the National Children s Hospital, Tallaght, Dublin 24, Ireland
Expert Opin Biol Ther 4:975-87. 2004..Infliximab, etanercept, alefacept and efalizumab are considered in detail...
- Biologic agents for the treatment of juvenile rheumatoid arthritis: current statusRuy Carrasco
Levinson Chair of Pediatric Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
Paediatr Drugs 6:137-46. 2004..Randomized trials are ongoing to better define both the efficacy and safety of these novel treatments for children with JRA and other rheumatic diseases...
- Integrating biologic therapies into a dermatology practice: practical and economic considerationsMark Craze
Texas Dermatology Associates, 5310 Harvest Hill, Suite 260, Dallas, TX 75230, USA
J Am Acad Dermatol 49:S139-42. 2003..This article provides information needed to guide dermatology practices in practical decisions regarding the use of biologic therapies...
- Preparing dermatology nurses: biologic therapy for psoriasisMelodie S Young
University of Texas, Arlington School of Nursing, USA
Dermatol Nurs 15:413-6, 419-23; quiz 424. 2003
- Upcoming biologic agents for the treatment of rheumatic diseasesJoseph C Shanahan
Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Alabama, USA
Curr Opin Rheumatol 15:226-36. 2003..This article reviews ongoing research on the treatment of rheumatic diseases with new and existing biologic agents...
- Update on the mechanisms and efficacy of biological therapies for psoriasisJohn Koo
UCSF Psoriasis Treatment Center, Department of Dermatology, University of California, 515 Spruce Street, San Francisco, CA 94118, USA
J Dermatol Sci 38:75-87. 2005....
- Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004Lyn Guenther
Department of Dermatology, University of Western Ontario, London, Ontario, Canada
J Cutan Med Surg 8:321-37. 2004..5..
- What are the risks of biologic therapy in rheumatoid arthritis? An update on safetyMichael H Weisman
Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
J Rheumatol Suppl 65:33-8. 2002..At this time, treating physicians must carefully weigh the benefits of these new biologics against their risks, particularly in patients at risk of infection...
- Musculoskeletal manifestations and autoimmune diseases related to new biologic agentsBoulos Haraoui
Universite de Montreal, RDU CHUM, Hopital Notre Dame, Montreal, Quebec, Canada
Curr Opin Rheumatol 18:96-100. 2006..One of the most common observations made during their use is the development of autoantibodies. The purpose of this paper is to review this phenomenon and its clinical implications...
- Use of prognostic markets to guide biologic therapies for rheumatoid arthritisChristopher A D'Arcy
J Rheumatol 29:2662; author reply 2662-3. 2002
- Cutaneous adverse events of biological therapy for psoriasis: review of the literatureA M Thielen
Department of Dermatology, University Hospital, Geneva, Switzerland
Dermatology 211:209-17. 2005..The object of this publication is to present an overview of the dermatological adverse events of these new treatment alternatives...
- Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefaceptJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
J Drugs Dermatol 4:544-55. 2005....
- Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided TherapyPrakash R Rai; Fiscal Year: 2011..for systemic cytotoxic therapy, photodynamic therapy (PDT) for localized cytotoxicity and simultaneous biological therapy to improve the treatment outcomes against HER2 positive and triple negative BrCa...
- Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided TherapyPrakash R Rai; Fiscal Year: 2013..for systemic cytotoxic therapy, photodynamic therapy (PDT) for localized cytotoxicity and simultaneous biological therapy to improve the treatment outcomes against HER2 positive and triple negative BrCa...
- Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis.SEOYOUNG CATHERINE KIM; Fiscal Year: 2013..Both Divisions have valuable resources including space, equipment, and knowledgeable faculty including experts in RA research as well as pharmacoepidemiology to help me achieve my goals. ..
- Translational Research Cancer Centers Consortium Annual MeetingGregory B Lesinski; Fiscal Year: 2012..Furthermore, it will allow for the opportunity to develop joint clinical trials using new promising biologic agents that will e available to patients in geographic regions with a traditionally high incidence of cancer. ..
- Monoclonal Antibody Drug Development for Alzheimer's DiseaseWilliam M Pardridge; Fiscal Year: 2012....
- EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism ofANNE SEARLS DEGROOT; Fiscal Year: 2013..program is to develop, define, validate and commercialize a novel, first-in-class, safe and effective biological therapy to prevent or treat T1D...
- Endoscopic Theranostics SystemSeok H Yun; Fiscal Year: 2010..tract diseases at the microscopic level and can simultaneously perform the tissue-specific and cell-specific biological therapy. In the event that gastrointestinal stem cells are available for use, this system will also be utilized to ..
- Randomized observation study of biologic therapy for rheumatoid arthritisLARRY W contact MORELAND; Fiscal Year: 2010..CCE studies and biomarker predictions are needed to provide rationale algorithms for biological therapy selection given the extensive array of therapies for treating RA...
- Longitudinal Comparative Effectiveness &Safety of Biologics in AutoimmunityJeffrey R Curtis; Fiscal Year: 2013....
- Molecular Response and Imaging-based Combination Strategies for Optimal PDTTayyaba Hasan; Fiscal Year: 2013..NMSC on the other hand has many options but the high incidence puts a heavy burden on society in terms of cost and suffering. ..
- A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic AsthmaNOLAN SIGAL; Fiscal Year: 2012..8 million annual US emergency department visits. The goal of this proposal is to develop and commercialize a novel human biologic capable of inhibiting acute allergic reactions as a treatment for severe allergy disease. ..
- Validation of CD6 as a New Target for Treating Multiple SclerosisFeng Lin; Fiscal Year: 2013..This study should validate CD6 as a new target for MS therapy and set the stage for further development of the anti-CD6 mAbs and soluble CD6-Fc protein as novel therapeutic agents for MS patients. ..
- Targeting surface-bound IgE as a novel allergy therapeuticKe Zhang; Fiscal Year: 2013..This application is directed at the development of a nove allergy therapeutic that is relevant to the public health. ..
- Discovering the Future of Pediatric IBD CareWallace Crandall; Fiscal Year: 2012..Our goal is to bring together a wide range of researchers and patients to develop a research plan for the next 5 years that will result in improved outcomes for these patients. ..
- TRAIL Mediated Apoptosis in Renal Cell CarcinomaPeter Clark; Fiscal Year: 2009..abstract_text> ..
- Postdoctoral Research Training in Biotherapy of CancerDavid L Bartlett; Fiscal Year: 2013..While this program is relatively new, the feedback from the faculty and trainees has been excellent, and the academic productivity has been significant. ..
- UTE MR Imaging of the Cartilaginous Endplate in the Lumbar SpineWon C Bae; Fiscal Year: 2013..This is likely to be useful for early intervention in treatment of disc degeneration and selection of patients suitable for biological therapy.
- Role of Natural Killer Cells in Myocarditis and Dilated CardiomyopathySufey Ong; Fiscal Year: 2013..All together, this research will provide a strong background for a novel and much needed biological therapy for myocarditis.
- RANDOMIZED ADJUVANT THERAPY OF HEAD AND NECK CANCERDong Shin; Fiscal Year: 2001....
- The third infections in cancer symposiumISSAM INAAM RAAD; Fiscal Year: 2012..There will be special emphasis on novel biological therapy and immunomodulation and future approaches in vaccination...
- Cardiac Fibrillation: Mechanisms and TherapyJames N Weiss; Fiscal Year: 2013..However, despite 50 years of molecular and cellular research, no biological therapy has yet emerged with comparable efficacy to the implantable cardioverter- defibrillator...
- TAS::75 0872::TAS SMARTT (11-8470187)Thomas VanCott; Fiscal Year: 2013..Section 4.2) . Provision of services as a US FDA-defined cGMP production faculty for biological therapy products. Processing, analyzing (Section 2.3 .5), storing, and shipping products (Section 4.1.2) produced...
- TAS::75 0872::TAS SMARTT (11-8470187)Thomas VanCott; Fiscal Year: 2012..Section 4.2) . Provision of services as a US FDA-defined cGMP production faculty for biological therapy products. Processing, analyzing (Section 2.3 .5), storing, and shipping products (Section 4.1.2) produced...
- TAS::75 0872::TAS SMARTT (11-8470187)Thomas VanCott; Fiscal Year: 2011..Section 4.2) . Provision of services as a US FDA-defined cGMP production faculty for biological therapy products. Processing, analyzing (Section 2.3 .5), storing, and shipping products (Section 4.1.2) produced...
- MECHANISM OF ACTION OF HERCEPTIN R IN BREAST CANCERJenny Chang; Fiscal Year: 2002....
- Improved influenza A virus vaccines using alpha-Gal epitope modificationCharles Link; Fiscal Year: 2009..We further propose that vaccines devloped with our adjuvant may also increase the immune response to influenza in the elderly. ..
- CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUMThomas Kipps; Fiscal Year: 1999..Through this CRC we will expedite research aimed at achieving a better understanding of the biologic basis of this disease and its eventual cure. ..
- Biologic therapy of Melanoma and Renal Cell CancerMichael Atkins; Fiscal Year: 2006..abstract_text> ..
- CONSTRUCTION OF AN ANTIBODY ENGINEERING LABORATORYDavid Gold; Fiscal Year: 1999..component of a major CMMI initiative to establish a major clinical cancer center program in the area of biological therapy. Indeed, all of the current NCI-funded investigators have awards in areas of biological therapy, primarily ..
- GENE THERAPY OF CANCER-IMMUNOLOGICAL APPROACHESMICHAEL LOTZE; Fiscal Year: 1993..Collectively this application supports extension of a vigorous, mature program in cancer therapeutics, applying the tools of molecular biology to enhance biologic therapies...
- Novel Targeted Therapy for Breast CancerGinette Serrero; Fiscal Year: 2007..activities will serve as the basis for a Phase II SBIR application as a basis for the development of novel biological therapy for breast cancer. Breast cancer remains one of the top three cancers to affect and cause mortality in women...
- Bladder Cancer Prevention by SilibininRajesh Agarwal; Fiscal Year: 2003..Standard treatment for bladder cancer includes surgery, chemo and radiation therapy, biological therapy, and combinations of these...
- IMMUNOLOGICAL BASIS OF SUSCEPTIBILITY TO TUBERCULOSISSamuel Behar; Fiscal Year: 2003..genes that govern it will facilitate a more rational approach to development and use of vaccines, drugs, and biological therapy. An aerosol route of inoculation will be used to infect intact mice that are either inherently resistant or ..
- Total Synthesis of Palmerolide ASUSANN WINBUSH; Fiscal Year: 2009..Stereo and structural isomers of palmerolide will be evaluated for their biological activity in regard to therapuetic potential as anti-melanoma agents. ..
- BRM MONITORING OF PEDIATRIC NEUROBLASTOMA/OSTEOSARCOMAPaul Sondel; Fiscal Year: 1991..e., colon, breast and lung adenocarcinomas)...
- NEURAL STEM CELLS AND NEURO-ONCOLOGYLawrence Recht; Fiscal Year: 2002..In total these studies are designed to develop unique models which in turn should form a base for new clinical approaches to the therapy of glioma. ..
- BIOLOGIC THERAPY RESEARCH CAREER DEVELOPMENT PROGRAMJohn Kirkwood; Fiscal Year: 2000....
- Targeting AKT as a novel therapy in pancreatic cancerRichard Bold; Fiscal Year: 2007..These results will provide mechanistic as well as pre-clinical data in support of our hypothesis and will allow for the development of novel therapy of human pancreatic cancer. [unreadable] [unreadable] [unreadable]..
- THIRD INTERNATIONAL CONGRESS OF THE METASTASIS RES SOCGarth Nicolson; Fiscal Year: 1990..Growth Factors and Metastasis (D. Tarin and M. Sporn, chairmen) 5. Cell Differentiation and Biological Therapy of metastases (M. Feldman and G. Heppner, chairmen) 6...
- RHOMOCYCSTEINASE FOR HOMOCYSTEINE ASSAYYuying Tan; Fiscal Year: 2002..The tHCY enzymatic kits for these applications will be ready for commercial launch at this point. PROPOSED COMMERCIAL APPLICATION: Not Available ..
- Inhibitors of 5alpha-reductase for acne therapyLingna Li; Fiscal Year: 2002..PROPOSED COMMERCIAL APPLICATIONS: Liposomal 4-MA will be developed as a topical selectively targeted therapeutic for acne for which they should be a very market. ..
- Discovery of novel fluorescent reporter genesMing Zhao; Fiscal Year: 2004..Reporters with spectral properties that can be used for whole-body imaging of tumors in the lung and their metastases will be candidates for further development for numerous applications of multi-color imaging. ..
- Enzyme therapy for hyperhomocysteinemiaYuying Tan; Fiscal Year: 2005..Phase II results will lead to an IND for MEGC-PEG-rMETase for end stage renal disease patients and other patients with intractable hyperhomocysteinemia and high cardiovascular disease mortality. ..
- Imageable tumor-targeting bacteriaMing Zhao; Fiscal Year: 2006..unreadable] [unreadable] [unreadable]..
- Targeted tumoricidal bacteriaMing Zhao; Fiscal Year: 2007..Future human trials of the tumor-killing bacteria can be held after the Phase I and Phase II grant periods are completed. [unreadable] [unreadable] [unreadable]..
- Adenoviral GFP targeting of metastatic human tumors using multiple delivery routeHiroyuki Kishimoto; Fiscal Year: 2008..Having obtained these results, we can move forward in the Phase II grant application with experiments to bring OBP-401 to the clinic for use in cancer surgery in human patients. [unreadable] [unreadable] [unreadable]..
- Orthotopic models of tumor angiogenesis and blood flowMeng Yang; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- Therapeutic hair follicle-derived neurospheresMeng Yang; Fiscal Year: 2007..Human hair- follicle bulge cells will be further characterized and developed for therapeutic potential for nerve regeneration in Phase III. [unreadable]..
- Dual-color tumor-host imaging modelsMeng Yang; Fiscal Year: 2007..These models have significant commercial potential for discovery and development of stroma-targeted and anti-angiogenesis drugs. [unreadable] [unreadable] [unreadable]..
- Lanthanides as Novel Anti-Arthritic AgentsChristopher Evans; Fiscal Year: 2004..A successful outcome to these studies will have identified the basis for a potential new, very inexpensive anti-rheumatic agent whose mode of action differs from that of existing drugs. ..
- Novel Nanostructured Calcium Phosphate for Gene Delivery to BoneChristopher Evans; Fiscal Year: 2005..2. To evaluate the ability of nCaP-vector constructs to enhance osteogenic responses in vivo. ..
- UVEITIS GENE-EXPRESSION PROFILINGJames Rosenbaum; Fiscal Year: 2008..The creation of a gene expression data base for patients with uveitis has the potential to clarify the pathogenesis of disease, establish new diagnostic tools, and provide a means for predicting prognosis. ..
- CHEMOTACTIC FACTORS IN ANIMAL MODELS OF UVEITISJames Rosenbaum; Fiscal Year: 2008..We believe that these aims are novel, innovative, especially suited to the skills and achievements demonstrated by our laboratory, and highly relevant to clarifying the pathogenesis of anterior uveitis. ..
- Delivery of Therapeutic Genes to Osteoarthritic JointsChristopher Evans; Fiscal Year: 2002....
- AAOS/NIH Mulit-Year Research Symposia for 2005-2009Christopher Evans; Fiscal Year: 2005....
- CLINICAL TRAILS IN PEDIATRIC RHEUMATOLOGYDaniel Lovell; Fiscal Year: 2004..2. Determine the long-term efficacy and safety of these treatment regimens in sJRA. ..
- Anterior Uveal Dendritic CellsJames Rosenbaum; Fiscal Year: 2004..These studies will clarify the function of the immune system within the eye and may suggest novel therapeutic approaches in the treatment of uveitis. ..
- IMMUNOLOGY/MOLECULAR BIOLOGY TRAINING IN OPHTHALMOLOGYJames Rosenbaum; Fiscal Year: 2007..The quality of the institution, the talents of the specific faculty, the abilities of the applicant pool, and the proven success of the program areadditional strengths of this application. ..